PABA

specialtyvitamin-like

At a glance

Best for
Adults with Peyronie's disease considering potassium para-aminobenzoate (POTABA) under clinician supervision
Typical dose
25–500 mg/day for supplements; 4–12 g/day for POTABA prescription use in fibrotic disease
Time to effect
Months (fibrotic conditions); not established for other uses
Main caution
Antagonizes sulfonamide antibiotics — must not be taken concurrently with sulfamethoxazole, dapsone, or sulfasalazine
Evidence strength: Limited throughout; topical UV protection now obsolete; fibrotic uses are weak evidence only

What is it

Para-aminobenzoic acid (PABA, 4-aminobenzoic acid) is a benzoic acid derivative bearing an amino group at the para position (C 7 H 7 NO 2 ). It is an intermediate in bacterial, plant, and fungal folate biosynthesis, where it is condensed with pterin to form dihydropteroate; the antifolate sulfonamide antibiotics are structural analogs that competitively block this step. PABA is not a vitamin for humans because we do not synthesize folate and obtain it preformed in our diet; it was historically classified as a B-complex vitamin under the now-obsolete designations 'vitamin Bx' or 'vitamin B10' and remains marketed as a vitamin-like supplement. Topically, PABA was widely used as a UVB-absorbing sunscreen agent until allergic and staining reactions led to its replacement by other UV filters.

Is it worth it for you?

Worth considering if…

  • You have Peyronie's disease and are under urologist supervision considering POTABA as an adjunct
  • You understand that evidence is weak and that high-dose use requires medical oversight

Probably skip if…

  • You are taking any sulfonamide antibiotic (sulfamethoxazole-TMP, dapsone, sulfasalazine) — direct antagonism
  • You have renal or hepatic impairment — high-dose PABA is hepatotoxic and contraindicated
  • You are pregnant or breastfeeding
  • You are buying it for hair color restoration or vitiligo — no credible evidence supports this use
  • You are buying it as a sunscreen — topical PABA is largely obsolete due to allergy and staining

Evidence at a glance

GoalEvidenceEffectBest fitTime
Peyronie's disease (potassium para-aminobenzoate)LimitedModest reduction in plaque size and pain in older RCT; small effectMen with Peyronie's disease, under urologist supervisionMonths
scleroderma and fibrotic skin disordersMixedNot consistently demonstratedAdults with scleroderma or morphea under specialist careMonths

Evidence for 2 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Peyronie's disease (potassium para-aminobenzoate)

Disease adjunct
Limited

Potassium para-aminobenzoate (POTABA) at 312 g/day has been used for Peyronie's disease based on the hypothesis that PABA may reduce fibrosis through modulation of oxidative stress and TGF-beta signaling. One older RCT found modest reduction in plaque size and penile pain. Evidence is limited to small, older studies with methodological limitations. POTABA at therapeutic doses requires medical supervision due to hepatotoxicity risk and GI burden.

Effect size: Modest reduction in plaque size and pain in older RCT; small effect
Time to effect: Months
Best fit: Men with Peyronie's disease, under urologist supervision
Less likely: Men with severe curvature requiring surgical intervention

Bottom line: Weak but not absent evidence — only consider under urologist supervision; self-dosing at therapeutic levels is not appropriate.

scleroderma and fibrotic skin disorders

Disease adjunct
Mixed

PABA and POTABA have been tried in scleroderma and other fibrosing skin conditions based on the same anti-fibrotic hypothesis as Peyronie's disease. Clinical trial results have been inconsistent and methodologically weak. No modern, adequately powered RCT has established efficacy. This use is largely historical and not part of current rheumatology treatment guidelines.

Effect size: Not consistently demonstrated
Time to effect: Months
Best fit: Adults with scleroderma or morphea under specialist care

Bottom line: Not supported by current evidence — this is a historical use without modern clinical backing.

Evidence is mixed

The few available trials are old, small, and of poor quality; results have not been reproduced in contemporary study designs.

How to take it

Typical dose
25–500 mg/day for supplements; 4–12 g/day for POTABA prescription (under physician supervision only)
Timing
With meals in divided doses to reduce GI upset at higher doses
With food
With food
Split dosing
Higher POTABA doses split into 4–6 doses throughout the day
How long to try
Peyronie's POTABA trials ran 3–12 months; shorter supplement use has no defined endpoint

What to track

  • Penile plaque or curvature change if using for Peyronie's (under urologist care)
  • Liver function tests at high doses
  • Signs of allergy or skin changes
  • Concurrent antibiotic prescriptions — stop PABA if sulfa antibiotic is prescribed

Safety

Common side effects

Nausea and vomiting at high doses, Anorexia, Skin rash, Fever

Serious risks

  • Hepatic toxicity (rare but documented at high doses, including jaundice and severe hepatitis)
  • Leukopenia at high doses
  • Hemolysis in G6PD deficiency
  • Contact dermatitis and photoallergy with topical use

Who should avoid it

  • Anyone on sulfonamide antibiotics (sulfamethoxazole-TMP, dapsone, sulfasalazine) — direct antagonism reduces antibiotic efficacy
  • People with renal or hepatic impairment
  • People with G6PD deficiency
  • Pregnant or breastfeeding women

Pregnancy & breastfeeding

Avoid during pregnancy and breastfeeding — insufficient safety data and potential fetal concern.

Interactions

sulfonamide antibiotics (sulfamethoxazole, dapsone, sulfasalazine)Major

PABA is a structural analog of sulfonamides and competitively reverses their mechanism — reduces or eliminates antimicrobial efficacy

anticoagulantsMinor

High-dose PABA may theoretically affect coagulation parameters; monitor if combining

Choosing a product

Look for

  • Dose in mg clearly stated
  • Third-party tested — high-dose PABA is not a typical OTC supplement scenario
  • Medical supervision required for POTABA therapeutic doses

Be skeptical of

  • 'Restores hair color'
  • 'Treats vitiligo'
  • 'Sun protection supplement'
  • 'Reverses aging skin'

References by claim

Peyronie's disease (potassium para-aminobenzoate)

  • Weidner et al., 2005PubMed (2005) link

scleroderma and fibrotic skin disorders

  • Clegg et al., 1994PubMed (1994) link

Track PABA with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.